Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Sudarshan K Sharma MD Limited-Gynecologic Oncology
mi
from
Hinsdale, IL
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Sudarshan K Sharma MD Limited-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
McFarland Clinic PC - Ames
mi
from
Ames, IA
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
McFarland Clinic PC - Ames
mi
from
Ames, IA
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Lake Huron Medical Center
mi
from
Port Huron, MI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Lake Huron Medical Center
mi
from
Port Huron, MI
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Delbert Day Cancer Institute at PCRMC
mi
from
Rolla, MO
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Delbert Day Cancer Institute at PCRMC
mi
from
Rolla, MO
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Atrium Health Cabarrus/LCI-Concord
mi
from
Concord, NC
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Atrium Health Cabarrus/LCI-Concord
mi
from
Concord, NC
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Akron General
mi
from
Akron, OH
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Akron General
mi
from
Akron, OH
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
mi
from
Mentor, OH
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
UH Seidman Cancer Center at Lake Health Mentor Campus
mi
from
Mentor, OH
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Indiana University-Bren and Melvin Simon Cancer Center
mi
from
Indianapolis, IN
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Indiana University-Bren and Melvin Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Polycystic Ovary Syndrome Genetics and Treatment Response
Polycystic Ovary Syndrome Genetics and Treatment Response
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Polycystic Ovary Syndrome Genetics and Treatment Response
Polycystic Ovary Syndrome Genetics and Treatment Response
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland
mi
from
Baltimore, MD
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Neely Center for Clinical Cancer Research, Tufts Medical Center
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Neely Center for Clinical Cancer Research, Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Amatuximab for High Mesothelin Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Amatuximab for High Mesothelin Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction in Overweight Early Pubertal Girls With Androgen Excess (CBS0004)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction in Overweight Early Pubertal Girls With Androgen Excess (CBS0004)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Early Pubertal Girls (JCM026)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Early Pubertal Girls (JCM026)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Gynecologic Oncology Associates-Newport Beach
mi
from
Newport Beach, CA
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Gynecologic Oncology Associates-Newport Beach
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Beebe Medical Center
mi
from
Lewes, DE
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials